Acne Vulgaris | Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Acne Vulgaris research study
What is the primary objective of this study?
The goal of this study is to enroll 250 participants that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page questionnaire designed to collect information on the diagnosis of severe acne and response to oral isotretinoin treatment. The aim is to identify genetic predictors of severe acne vulgaris and the outcome of oral isotretinoin treatment.
Who is eligible to participate?
Inclusion Criteria: - Diagnosed with severe acne while age > 12 and < 18, and - Completed at least one course of oral isotretinoin treatment; OR started treatment but discontinued prior to completion due to adverse side effects (with the exception of dry skin - see \"exclusion criteria\"); OR are currently undergoing and plan to complete treatment Exclusion Criteria: - Patients who are not willing to participate in this study - Patients who experienced inflammatory bowel disease (IBD) prior to oral isotretinoin treatment - Patients who did not complete the oral isotretinoin treatment because of pregnancy, dry skin, or reasons other than adverse side effects listed above - Patients who are not willing to or cannot provide a blood sample for Murdock Study
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: September 2011
Completed Date: August 2015
Primary Outcome: Therapeutic response to isotretinoin
Secondary Outcome: Adverse reaccion to isotretinoin
Study sponsors, principal investigator, and references
Principal Investigator: Russell Hall, MD
Lead Sponsor: Duke University